Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impedance Cardiography-Guided Therapy for Preeclampsia Prevention
NCT03245970Phase 1Withdrawn
- Sponsor
- University of Tennessee Medical Center
- Start
- Apr 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of labetalol, nifedipine GITS and atenolol in hypertension (HTN) (2 arms), sponsored by University of Tennessee Medical Center. Primary endpoint: Rates of preeclampsia in chronically hypertensive pregnant women at 2 years. Planned start Apr 2017; status: withdrawn.
02
Drugs
labetalolnifedipine GITSatenolol
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03245970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245970.